Covance agrees on China joint venture with WuXi
This article was originally published in Scrip
Executive Summary
In another move by an international contract research organisation to tap into the expertise and lower costs in China, the US-based CRO Covance has struck a basic agreement to form an equally owned joint venture with WuXi PharmaTech, a Shanghai-based provider of pharmaceutical services.